ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

1:00PM-1:15PM: Abstract Number: 0783

Pain reduction and functional improvements following a non-invasive biomechanical intervention for gait rehabilitation may explain a reduction in healthcare claims. An observational study

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (0783–0788)

1:00PM-1:15PM: Abstract Number: 0789

Short Form 36 (SF-36) Health Survey Questionnaire in Health-Related Quality of Life Assessment in Patients with Inflammatory Myopathies

Abstracts: Patient Outcomes, Preferences, & Attitudes (0789–0794)

1:00PM-1:15PM: Abstract Number: 0788

Spatiotemporal Gait Differences Between Fallers and Non-Fallers in People with Knee Osteoarthritis

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (0783–0788)

1:15PM-1:30PM: Abstract Number: 0778

Clinical significance of non-infectious increased procalcitonin in Still’s disease: A predictor of macrophage activation syndrome

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

1:15PM-1:30PM: Abstract Number: 0796

Deciphering Synovial Fluid Immune Dysregulation in Rheumatoid Arthritis through Cytokine Profiling and Single-Cell Transcriptomics

Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

1:15PM-1:30PM: Abstract Number: 0790

Diabetes Risk in Psoriasis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs: Target Trial Emulation Using Nationwide Data

Abstracts: Patient Outcomes, Preferences, & Attitudes (0789–0794)

1:15PM-1:30PM: Abstract Number: 0784

Physical Activity and Exercise Therapy Reduce the Transition from Acute to Chronic Low Back Pain in the Community

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (0783–0788)

1:15PM-1:30PM: Abstract Number: 0802

Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study

Abstracts: Systemic Lupus Erythematosus – Treatment I (0801–0806)

1:15PM-1:30PM: Abstract Number: 0808

Spatial Transcriptomics Show Fibroblast LIF Receptor Drives Fibrosis in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

1:30PM-1:45PM: Abstract Number: 0791

Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine

Abstracts: Patient Outcomes, Preferences, & Attitudes (0789–0794)

1:30PM-1:45PM: Abstract Number: 0809

Human blood vessel organoids as a model of vasculopathy in systemic sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

1:30PM-1:45PM: Abstract Number: 0803

Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials

Abstracts: Systemic Lupus Erythematosus – Treatment I (0801–0806)

1:30PM-1:45PM: Abstract Number: 0779

Interim Results of a Randomized Placebo Controlled Study of IL-1 Inhibitor Goflikicept in Patients With Familial Mediterranean Fever

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

1:30PM-1:45PM: Abstract Number: 0785

It Takes a Community: Exploring the Importance of Community-Level Social Determinants of Health in Total Knee Arthroplasty Outcomes

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (0783–0788)

1:30PM-1:45PM: Abstract Number: 0797

Spatial transcriptomics identifies density-sensing fibroblasts in synovial lining

Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].